An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

The Australian biotech could potentially be on the hook for more than $1bn after its Wet AMD therapy failed to show impact ...

UNITY anticipates the complete 36-week data results of the remaining patients in the second quarter of 2025.

Ten drugs were classified as low or no added therapeutic benefit compared with alternatives, accounting for $6.7 billion in ...

Complete 36-week results from the ASPIRE study involving 52 patients are expected in the second quarter of 2025.

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces ...

The phase 3 COAST trial investigating 2 mg sozinibercept for the treatment of wet age-related macular degeneration in ...

Unity Biotechnology has reported outcomes from its randomised Phase IIb ASPIRE study of intravitreal UBX1325 for diabetic ...

Broker Canaccord Genuity says this ASX share potentially 'has no value from here'. Here's what is happening with this ...

Intravitreal UBX1325 helped patients with diabetic macular edema gain vision but failed to meet its primary analysis endpoint in the ASPIRE clinical trial, according to a press release from Unity ...